INVESTORS & MEDIA

TARRYTOWN, N.Y., March 22, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the appointment of Michael Aberman, M.D., as Vice President, Strategy and Investor Relations. In the Strategy role, Dr. Aberman will report directly to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer, and for Investor Relations he will report directly to Murray A. Goldberg, Chief Financial Officer. Peter Dworkin, Vice President, will continue to be responsible for Corporate Communications, reporting to Mr. Goldberg.

Prior to joining Regeneron, Dr. Aberman spent six years as a Wall Street research analyst covering the biotechnology industry. Most recently, he was Director and Senior Biotechnology Analyst at Credit Suisse and prior to that, Vice President and Biotech Analyst at Morgan Stanley. Before moving to Wall Street, Dr. Aberman was Director of Business Development at Antigenics, Inc., an oncology-focused biotechnology company. Dr. Aberman received his medical degree from the University of Toronto, completed residency training at New York Presbyterian Hospital, and received an M.B.A. from The Wharton School of Business.

"We are thrilled that Michael has joined our management team," said Dr. Schleifer. "Michael brings a unique combination of knowledge and experience gained from more than twelve years as a physician, biotech executive, and Wall Street analyst. We look forward to benefiting from his insights as we work to develop and commercialize important new medicines."

"I am very excited to be joining Regeneron at a pivotal time in its history," said Dr. Aberman. "2010 will bring results from multiple Phase 3 trials in gout, age-related macular degeneration, and cancer. In addition, the expanded collaboration with sanofi-aventis positions Regeneron to capitalize on its truly world class capabilities to build a robust pipeline of antibody-based product candidates over the coming years."

About Regeneron

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Forward Looking Statement

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that are superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2009. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

    Contact Information:

    Peter Dworkin                Laura Lindsay
    Investor Relations           Media Relations
    914.345.7640                 914.345.7800
    peter.dworkin@regeneron.com  laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved